Mitigating risk in the development of clinical antibodies

The commercial development of therapeutic antibodies is not without its risks.

Bioinformatics, Biomedical Research, Business, Immunotherapy, Protein Engineering, Structural BiologyGordon WebsterJune 8, 2021antibodies, protein engineering, structural biology, bioinformatics, immunology, immunotherapy

A potential route to antiviral therapy for coronavirus.

Deeper knowledge of the mechanisms of coronavirus replication and assembly has been obtained from structural biology.

Biomarkers, ImmunotherapyGordon WebsterMarch 22, 2020covid19, sars_cov_2, sarscov2, structuralbiology, xraycrystallography, proteins, proteaseinhibitors, antiviral, bioinformatics, drugdevelopment, pandemic, coronavirus

The art of deimmunizing therapeutic proteins

As designers of therapeutic proteins and antibodies, how can we take advantage of an immunological “short-cut”, to make our molecules less immunogenic?